Article
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors.
Cancer research - 16 Jan 2026
Stern Yaakov E, Ghosh Pompom, Peroza John, Solanki Hitendra S, Imbody Denis, Bridenstine Liznair, Pandurangan Thiyagamurthy, Frydman Sylvia M, Nickens Kathryn N, Walker-Mimms Hannah L, Suvarna Kruthi, Chaudhary Neelkamal, Monastyrskyi Andrii, Duckett Derek, Haura Eric B
Abstract excerpt
The onset of acquired resistance limits the efficacy of KRASG12C inhibitors in patients with lung cancer. Experiments in preclinical model systems and retrospective analyses of patients treated with these inhibitors have both suggested that the activation of DNA repair pathways and G2/M kinases is common in lung cancers with acquired resistance to KRASG12C inhibitors. In this study, we identified a shared...
Read the complete abstract on PubMedTopics
- Humans
- Drug Resistance, Neoplasm
- Proto-Oncogene Proteins p21(ras)
- Animals
- Mice